Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.58 |
| ▸ | NPY2R | P49146 | 3/20 | 0.58 |
| ▸ | NPY4R | P50391 | 3/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.55 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466124 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL3486221 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL3486226 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29388140 | 0.94 | GHSR (0.55) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29534023 | 0.94 | GHSR (0.55) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL14509563 | 0.91 | GHSR (0.65) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL31404052 | 0.90 | GHSR (0.68) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL21185972 | 0.90 | IL23R (0.65) | KISS1RIL23R | |
| SCHEMBL16358972 | 0.88 | GHSR (0.61) | GHSRUTS2R | |
| SCHEMBL30053610 | 0.88 | GHSR (0.71) | GHSRNPY1RNPY2RNPY4RUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089542-A1 | PEPTIDE-POLYMER COMPOSITE MATERIAL FOR SURFACE MODIFICATION OF STEM CELLS, HAVING ANGIOGENESIS-INDUCING PEPTIDE APPLIED THERETO, AND COMPOSITION FOR TREATING LIVER DAMAGE | 동국대학교 산학협력단 | 2026-04-30 | — | — | WO | claimed |
| US-20260035408-A1 | WKYMVm peptide analogues having six residues and uses thereof | RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV (KR) | 2026-02-05 | — | — | US | claimed |
| US-20250032573-A1 | IMMUNITY-ENHANCING PEPTIDE ANALOGS AND USES THEREOF | Research & Business Foundation Sungkyunkwan University (KR) | 2025-01-30 | — | — | US | claimed |
| WO-2024172437-A1 | HYALURONIC ACID DERIVATIVE-WKYMVM CONJUGATE AND USE THEREOF | 주식회사 하이셀텍 | 2024-08-22 | — | — | WO | claimed |
| US-20240173375-A1 | CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO | BIOTEMPT B.V. (NL) | 2024-05-30 | — | — | US | claimed |
| EP-4301391-A1 | CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO | Biotempt B.V. (NL) | 2024-01-10 | — | — | EP | claimed |
| US-20220409775-A1 | INJECTABLE HYDROGEL COMPOSITION HAVING ENDOGENOUS PROGENITOR OR STEM CELL RECRUITMENT AND INDUCTION OF VASCULAR DIFFERENTIATION OF RECRUITED CELLS | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-12-29 | — | — | US | claimed |
| EP-4062951-A2 | INJECTABLE HYDROGEL COMPOSITION CAPABLE OF CAPTURING ENDOGENOUS PROGENITOR CELLS OR STEM CELLS, AND INDUCING VASCULAR DIFFERENTIATION OF CAPTURED CELLS | Ajou University Industry-Academic Cooperation Foundation (KR) | 2022-09-28 | — | — | EP | claimed |
| WO-2022186690-A1 | CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO. | BIOTEMPT B.V. (NL) | 2022-09-09 | — | — | WO | claimed |
| CN-122070280-A | FPR1 modulators, compositions comprising the modulators, and methods of use thereof | 百放开曼有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026089542-A1 | PEPTIDE-POLYMER COMPOSITE MATERIAL FOR SURFACE MODIFICATION OF STEM CELLS, HAVING ANGIOGENESIS-INDUCING PEPTIDE APPLIED THERETO, AND COMPOSITION FOR TREATING LIVER DAMAGE | 동국대학교 산학협력단 | 2026-04-30 | — | — | WO | disclosed |
| EP-4714371-A2 | ANASTOMOSIS FORMATION WITH MAGNETIC DEVICES HAVING TEMPORARY RETENTION MEMBER | GT Metabolic Solutions, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4213744-B1 | ANASTOMOSIS FORMATION WITH MAGNETIC DEVICES HAVING TEMPORARY RETENTION MEMBER | GT METABOLIC SOLUTIONS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035408-A1 | WKYMVm peptide analogues having six residues and uses thereof | RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV (KR) | 2026-02-05 | — | — | US | disclosed |
| WO-2022194240-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD. (CAYMAN) (KY) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022186690-A1 | CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO. | BIOTEMPT B.V. (NL) | 2022-09-09 | — | — | WO | disclosed |
| US-20220169693-A1 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2022-06-02 | — | — | US | disclosed |
| EP-3981878-A1 | FPR2 RECEPTOR AGONIST APTAMERS AND USES THEREOF | Universidad Carlos III de Madrid (ES) | 2022-04-13 | — | — | EP | disclosed |
| US-20220087678-A1 | ANASTOMOSIS FORMATION WITH MAGNETIC DEVICES HAVING TEMPORARY RETENTION MEMBER | GT METABOLIC SOLUTIONS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169693-A1 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | AGER, IGSF11, ICAM1 | GHSR 457/4885NPY1R 4319/4885NPY2R 4469/4885 |
| US-20260035408-A1 | WKYMVm peptide analogues having six residues and uses thereof | HNMT, LTK, FPR3 | GHSR 959/4885NPY1R 91/4885NPY2R 64/4885 |
| US-20250032573-A1 | IMMUNITY-ENHANCING PEPTIDE ANALOGS AND USES THEREOF | FPR3, FPR1, FPR2 | GHSR 1228/4885NPY1R 109/4885NPY2R 107/4885 |
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | GHSR 520/4885NPY1R 40/4885NPY2R 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.